


GWG Review of Clinical Program Applications

Gil Sambrano


Director of Portfolio Development and Review

Clinical Stage Programs

CLINICAL STAGE



CLIN 1



CLIN 2



CLIN 3

Scoring System for 2.0 Applications

- **Score of “1”**

Exceptional merit and warrants funding.

- **Score of “2”**

Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement.

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted **for at least 6 months.***

Applications are scored by all scientific members of the GWG with no conflict.

CLIN2-08839: Clinical Trial of New Device Configurations for Diabetes Therapy

Therapy: Human embryonic stem cell (hESC)-derived pancreatic progenitor cells delivered in an encapsulation device

Indication: Type 1 diabetes

Goal: Test different configurations of an empty encapsulation device in patients to optimize for use in a combination product with hESC-derived pancreatic progenitor cells.

Major Proposed Activities:

- Manufacture and quality control of different configurations of encapsulation device
- Enroll subjects in the clinical trial
- Analyze clinical data

Funds Requested: \$2,582,074 (\$1,207,799 Co-funding)

CLIN2-08839: Clinical Trial of New Device Configurations for Diabetes Therapy

Budget Review: Pass

GWG Score: 1* Exceptional merit, warrants funding

- Votes for score of 1: **5**
- Votes for score of 2: **5**
- Votes for score of 3: **1**

*Vote by GWG to assign a score of “1”: 9 (yes), 8 (no), 1 (abstention)

CIRM Team Recommendation: Do not fund, but allow revision and immediate resubmission for GWG evaluation